Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Visceral leishmaniasis: An overview of vaccine adjuvants and their applications
Sneha Ratnapriya, Keerti Keerti, Amogh A. Sahasrabuddhe, et al.
Vaccine (2019) Vol. 37, Iss. 27, pp. 3505-3519
Closed Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Methods to improve the immunogenicity of plasmid DNA vaccines
Dalinda Eusébio, Ana R. Neves, Diana Costa, et al.
Drug Discovery Today (2021) Vol. 26, Iss. 11, pp. 2575-2592
Closed Access | Times Cited: 70
Current leishmaniasis drug discovery
Alessandra C. Pinheiro, M.V.N. De Souza
RSC Medicinal Chemistry (2022) Vol. 13, Iss. 9, pp. 1029-1043
Open Access | Times Cited: 36
Leishmania vaccine development: A comprehensive review
Isha Saini, Jyoti Joshi, Sukhbir Kaur
Cellular Immunology (2024) Vol. 399-400, pp. 104826-104826
Closed Access | Times Cited: 8
A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection
Daniela P. Lage, Patrícia A.F. Ribeiro, Daniel Dias, et al.
npj Vaccines (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 43
Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design
Carolin Loos, Margherita Coccia, Arnaud M. Didierlaurent, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 15
The Delay in the Licensing of Protozoal Vaccines: A Comparative History
M Palatnik, Dirlei Nico
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 33
A Recombinant Chimeric Protein-Based Vaccine Containing T-Cell Epitopes from Amastigote Proteins and Combined with Distinct Adjuvants, Induces Immunogenicity and Protection against Leishmania infantum Infection
Daniela P. Lage, Danniele L. Vale, Flávia P. Linhares, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1146-1146
Open Access | Times Cited: 22
Targeting Tumor Heterogeneity with Neoantigen-Based Cancer Vaccines
Saranya Pounraj, Shuxiong Chen, Linlin Ma, et al.
Cancer Research (2023) Vol. 84, Iss. 3, pp. 353-363
Closed Access | Times Cited: 11
Efficacy of LaAg Vaccine Associated with Saponin Against Leishmania amazonensis Infection
Mirian França de Mello, Patrícia de Almeida Machado, Pollyane Sousa Gomes, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 129-129
Open Access
Screening helper T lymphocyte epitopes based on IFN-γ/IL-10 ratio for developing a novel multi-epitope vaccine candidate using Wolbachia surface protein as an adjuvant against visceral leishmaniasis
Jianhui Zhang, Tianhang Lv, Shuoyan Tan, et al.
Parasites & Vectors (2025) Vol. 18, Iss. 1
Open Access
A new chimeric protein composed by T-cell epitopes from peroxidoxin and pyridoxal kinase proteins is protective against visceral leishmaniasis
Daniela P. Lage, Danniele L. Vale, Marcela G P Silva, et al.
Cellular Immunology (2025) Vol. 411-412, pp. 104949-104949
Closed Access
Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis
Daniela P. Lage, Patrícia A.F. Ribeiro, Daniel Dias, et al.
Vaccines (2020) Vol. 8, Iss. 2, pp. 289-289
Open Access | Times Cited: 21
A specific Leishmania infantum polyepitope vaccine triggers Th1-type immune response and protects against experimental visceral leishmaniasis
Thais Lopes Valentim Di Paschoale Ostolin, Miriã Rodrigues Gusmão, Fernando Augusto Siqueira Mathias, et al.
Cellular Immunology (2022) Vol. 380, pp. 104592-104592
Closed Access | Times Cited: 12
Immunoinformatics-based multi-epitope containing fused polypeptide vaccine design against visceral leishmaniasis with high immunogenicity and TLR binding
Pawan Kumar, Prakash Kumar, Ashish Shrivastava, et al.
International Journal of Biological Macromolecules (2023) Vol. 253, pp. 127567-127567
Closed Access | Times Cited: 7
Combining Killed Vaccine Candidate with Different Adjuvants to Determine Prophylactic Potential against Leishmaniasis
Kübra Kelleci, Adil Allahverdiyev, Melahat Bağırova, et al.
Acta Parasitologica (2024) Vol. 69, Iss. 3, pp. 1613-1620
Closed Access | Times Cited: 2
Development of nano-carriers forLeishmaniavaccine delivery
Anis Askarizadeh, Ali Badiee, Ali Khamesipour
Expert Opinion on Drug Delivery (2020) Vol. 17, Iss. 2, pp. 167-187
Closed Access | Times Cited: 18
Leishmania infantum amastin protein incorporated in distinct adjuvant systems induces protection against visceral leishmaniasis
Patrícia A.F. Ribeiro, Danniele L. Vale, Daniel Dias, et al.
Cytokine (2020) Vol. 129, pp. 155031-155031
Closed Access | Times Cited: 16
DEC-205 receptor-mediated long-circling nanoliposome as an antigen and Eucommia ulmoides polysaccharide delivery system enhances the immune response via facilitating dendritic cells maturation
Haibo Feng, Xiaonong Yang, Jing Fan, et al.
Drug Delivery (2020) Vol. 27, Iss. 1, pp. 1581-1596
Open Access | Times Cited: 16
A Chimera of Th1 Stimulatory Proteins of Leishmania donovani Offers Moderate Immunotherapeutic Efficacy with a Th1-Inclined Immune Response against Visceral Leishmaniasis
Sneha Ratnapriya, Keerti Keerti, Narendra Kumar Yadav, et al.
BioMed Research International (2021) Vol. 2021, pp. 1-14
Open Access | Times Cited: 14
Immune induction by adjuvanted Leishmania donovani vaccines against the visceral leishmaniasis in BALB/c mice
Deepak Goyal, Poonam Keshav, Sukhbir Kaur
Immunobiology (2021) Vol. 226, Iss. 2, pp. 152057-152057
Closed Access | Times Cited: 13
A recombinant Leishmania amastigote-specific protein, rLiHyG, with adjuvants, protects against infection with Leishmania infantum
Amanda S. Machado, Daniela P. Lage, Danniele L. Vale, et al.
Acta Tropica (2022) Vol. 230, pp. 106412-106412
Closed Access | Times Cited: 9
Lipophosphoglycan-3 protein from Leishmania infantum chagasi plus saponin adjuvant: A new promising vaccine against visceral leishmaniasis
Sabrina de Oliveira Emerick, Thaís Vieira de Carvalho, Bianca Meirelles Miranda, et al.
Vaccine (2020) Vol. 39, Iss. 2, pp. 282-291
Open Access | Times Cited: 12
Evaluation of the protective efficacy of a Leishmania protein associated with distinct adjuvants against visceral leishmaniasis and in vitro immunogenicity in human cells
Patrícia A.F. Ribeiro, Daniel Dias, Daniela P. Lage, et al.
Parasitology Research (2020) Vol. 119, Iss. 8, pp. 2609-2622
Closed Access | Times Cited: 11
Immunogenicity and protective efficacy of tuzin protein as a vaccine candidate in Leishmania donovani-infected BALB/c mice
Moodu Devender, Prince Sebastian, Vijay Kumar Maurya, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 1
Effects of vitamin A and vitamin E on attenuation of amphotericin B-induced side effects on kidney and liver of male Wistar rats
Aref Salehzadeh, Alireza Salehzadeh, Amir Hossein Maghsood, et al.
Environmental Science and Pollution Research (2020) Vol. 27, Iss. 26, pp. 32594-32602
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top